Unknown

Dataset Information

0

Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus.


ABSTRACT: BACKGROUND AND AIMS:This multicenter trial compared immediate-release tacrolimus (IR-T) vs prolonged-release tacrolimus (PR-T) in de novo kidney, liver, and heart transplant recipients aged <16 years. Each formulation had similar pharmacokinetic (PK) profiles. Follow-up efficacy and safety results are reported herein. MATERIALS AND METHODS:Patients, randomized 1:1, received once-daily, PR-T or twice-daily, IR-T within 4 days of surgery. After a 4-week PK assessment, patients continued randomized treatment for 48 additional weeks. At Year 1, efficacy assessments included the number of clinical acute rejections, biopsy-confirmed acute rejection (BCAR) episodes (including severity), patient and graft survival, and efficacy failure (composite of death, graft loss, BCAR, or unknown outcome). Adverse events were assessed throughout. RESULTS:The study included 44 children. At Year 1, mean ± standard deviation tacrolimus trough levels were 6.6 ± 2.2 and 5.4 ± 1.6 ng/mL, and there were 2 and 7 acute rejection episodes in the PR-T and IR-T groups, respectively. No cases of graft loss or death were reported during the study. The overall efficacy failure rate was 18.2% (PR-T n = 1; IR-T n = 7). CONCLUSIONS:In pediatric de novo solid organ recipients, the low incidence of BCAR and low efficacy failure rate suggest that PR-T-based immunosuppression is effective and well tolerated to 1-year post-transplantation.

SUBMITTER: Vondrak K 

PROVIDER: S-EPMC6900073 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus.

Vondrak Karel K   Parisi Francesco F   Dhawan Anil A   Grenda Ryszard R   Webb Nicholas J A NJA   Marks Stephen D SD   Debray Dominique D   Holt Richard C L RCL   Lachaux Alain A   Kelly Deirdre D   Kazeem Gbenga G   Undre Nasrullah N  

Clinical transplantation 20190919 10


<h4>Background and aims</h4>This multicenter trial compared immediate-release tacrolimus (IR-T) vs prolonged-release tacrolimus (PR-T) in de novo kidney, liver, and heart transplant recipients aged <16 years. Each formulation had similar pharmacokinetic (PK) profiles. Follow-up efficacy and safety results are reported herein.<h4>Materials and methods</h4>Patients, randomized 1:1, received once-daily, PR-T or twice-daily, IR-T within 4 days of surgery. After a 4-week PK assessment, patients conti  ...[more]

Similar Datasets

| S-EPMC5024030 | biostudies-literature
| S-EPMC6624387 | biostudies-literature
| S-EPMC7412936 | biostudies-literature
| S-EPMC6824349 | biostudies-literature
| S-EPMC8274734 | biostudies-literature
| S-EPMC9397503 | biostudies-literature
| S-EPMC6752107 | biostudies-literature
| S-EPMC6852421 | biostudies-literature
| S-EPMC5542786 | biostudies-literature
| S-EPMC6728630 | biostudies-literature